


A Validated LC Method for the Quantitation of Cefotaxime in pH-Sensitive Nanoparticles



2010, 71, 373–381

Rosa Pereira¹, Tommy Julianto¹, Peh-Kim Ang², Sharon Sheue-Nee Ling³, Carlos Mauricio Barbosa⁴, Kah-Hay Yuen², Abu Bakar Abdul Majeed¹,✉

¹ Nanopharmacy Research Unit, Faculty of Pharmacy, Universiti Teknologi MARA, Shah Alam, Selangor, Malaysia; E-Mail: abubakar@salam.uitm.edu.my; adrianapmak@yahoo.com

² School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pinang, Malaysia

³ Hovid Bhd, 121, Jalan Tunku Abdul Rahman, Ipoh, Perak, Malaysia

⁴ Serviço de Tecnologia Farmacêutica, Faculdade de Farmácia da Universidade do Porto and CEQUIMED-UP, Centro de Química Medicinal da Universidade do Porto, Porto, Portugal

Received: 7 September 2009 / Revised: 12 December 2009 / Accepted: 18 December 2009
Online publication: 14 March 2010

Abstract

A sensitive and rapid routine LC method was validated for measuring cefotaxime incorporated in three different pH-sensitive nanoparticles. The drug was chromatographed on a C18 reversed-phase column; the mobile phase used was 0.05 M aqueous ammonium acetate, acetonitrile and tetrahydrofuran (87:11:2, v/v) adjusted to pH 5.5 with acetic acid. The flow rate was 1 mL min⁻¹ and cefotaxime was quantified at 254 nm, with a sensitivity range of 0.005 AUFS. The validated method was specific, linear ($R^2 \geq 0.999$), precise and accurate in a concentration range of 0.2–50.0 µg mL⁻¹. The method was rapid, selective and suitable for evaluation of cefotaxime in pH-sensitive Eudragit nanoparticles.

Keywords

Column liquid chromatography
pH-Sensitive nanoparticles
Cefotaxime
Eudragit

Introduction

Cefotaxime sodium is a water soluble semi-synthetic third-generation cephalosporin (Fig. 1). It is a peptidomimetic drug which exists as zwitterionic compound at physio-

logical pH and unable to permeate the gastrointestinal mucosa. Thus, it is not appreciably absorbed on peroral administration and consequently presents poor oral bioavailability, falling into the class III of the Biopharmaceutics Classification System [1].

Due to the cefotaxime sodium similarity in structure and biopharmaceutical profile with proteins and peptides it might be used as a model drug for characterizing the incorporation of peptidomimetics in nanocarriers. This is important since the majority of the newly developed therapeutic molecules are peptides or proteins [2, 3]. Nanocarriers, such as pH-sensitive nanoparticles, may constitute an alternative to overcome the difficulties related to poor permeability of peptidomimetic compounds and improve their oral bioavailability. This approach has been applied to different drugs [4–7].

pH-Sensitive nanoparticles are matrix-type disperse systems of nanometer size [8]. They can protect labile macromolecules from stomach acid and the first-pass metabolism in the gastrointestinal tract [9] and reduce side effects [10]. Moreover, due to their inherent pH-sensitive property, the incorporated drug can be released at a specific pH within the gastrointestinal tract, as close as possible to its absorption window [7, 11]. Acrylic polymers such as Eudragit L100, Eudragit L100-55 and Eudragit S100 are co-polymers of poly(methacrylic acid and methacrylate), which can dissolve




Fig. 1. Chemical structure of cefotaxime sodium

rapidly at specific pH values. Thereby, the release properties of nanoparticles formed by these polymers exhibit significant pH-sensitivity [7].

In order to test the usefulness of Eudragit pH-sensitive nanoparticles as potential carriers to improve cefotaxime sodium oral bioavailability, we are carrying out *in vivo* studies for formulations prepared with different types of Eudragit. To facilitate the pharmaceutical development of cefotaxime sodium-containing nanoparticle formulations an analytical method for the quantitation of drug and characterization of its *in vitro* release profile is needed to guarantee the reliability of the results [12, 13]. Different methods for determination of cefotaxime sodium in simple solutions and plasma have been described [1, 14–22]. However, some important drawbacks, such as complex sample preparation and/or incomplete validation, were observed for the reported methods. As such, new methodologies have been developed to overcome these limitations when a plasma matrix is used [23–25]. The aim of the present work was to adapt this method for the quantitation of cefotaxime which was entrapped for the first time into pH-sensitive nanoparticles and to validate it through the methodologies and parameters recommended by the International Conference on Harmonization [26, 27], which are similar to the ones established by the United States Pharmacopoeia 29 (USP 29) [28].

Experimental

Chemicals and Reagents

Cefotaxime sodium was obtained from Orchid Chemicals and Pharmaceuticals (Chennai, India). Eudragit L100,

Eudragit L100-55 and Eudragit S100 were purchased from Degussa (Singapore). Disodium hydrogen orthophosphate was obtained from Fisher Scientific (Singapore). Acetonitrile was acquired from LAB-SCAN (Bangkok, Thailand). Ammonium acetate, perchloric acid (70%, *w/w*) and tetrahydrofuran were obtained from Merck (Darmstadt, Germany). Glacial acetic acid and hydrochloric acid were purchased from BDH (Poole, England). Sodium chloride was acquired from Fluka (Deisenhofen, Germany). Pepsin, pancreatin and monobasic potassium phosphate were purchased from Sigma (St. Louis, MO, USA). LC grade water was obtained by a MilliQ system (Millipore, Singapore). All solvents and chemicals used were of analytical or LC grade.

Apparatus

The experiments were performed on an Waters Breeze LC system (Waters, Milford, MA, USA), comprising a Waters 1525 Binary LC pump, a 717 Plus autosampler, a Rheodyne 7725i sample injector, a Symmetry C18 (5 μm , 4.6 \times 250 mm) column, fitted with a Universal Sentry Guard Holder packed with Nova-Pack cartridge, a 2487 dual wavelength absorbance detector and a computer with a Breeze software that controls the system and displays the results. The pH of the solutions was measured by a pH-meter from Mettler Toledo Seven Easy (Mettler Toledo, Shah Alam, Malaysia).

Chromatographic Conditions

The mobile phase was composed of a mixture of 0.05 M aqueous ammonium acetate–acetonitrile–tetrahydrofuran (87:11:2, *v/v*), adjusted to pH 5.5 with glacial acetic acid. The mobile phase was filtered using a 0.45 μm Teflon membrane filter (Millipore, Milford, MA, USA) and degassed by sonication prior to use. It was pumped through the system at a flow rate of 1.0 mL min^{-1} by isocratic elution. All the determinations were performed at ambient temperature. The detection wavelength was set at

254 nm and the sensitivity adjusted to 0.005 absorbance units full scale (AUFS). The samples were quantified based on the peak height.

Nanoparticle Preparation and Characterization

pH-Sensitive nanoparticles were prepared by a novel pH-sensitive nanoprecipitation method, which is under optimization [11]. Briefly, a 0.7% polymeric solution (Eudragit L100, Eudragit L100-55 or Eudragit S100) was added with an amount of cefotaxime sodium to obtain a 1:1 (*w/w*) polymer:drug ratio. Then, a precipitating solution (1 M acetic acid) was added under moderate stirring. Obtained nanodispersions were left at room temperature for established periods of time. Non-incorporated drug was separated by ultracentrifugation at 90,000 $\times g$ for 4 h (Optima LE 80-K ultracentrifuge, Beckman Coulter, Fullerton, CA, USA). Pelleted nanoparticles were quickly frozen by immersion into liquid nitrogen and freeze-dried without heating for 24 h (Labconco Freeze Dry System, Kansas, MI, USA). Blank nanoparticles were prepared by the same method but omitting the addition of drug.

Size and zeta potential of nanoparticles were measured using a Zetasizer Nano ZS (Malvern instruments, Malvern, UK).

Calculation of the percentage of nanoparticle recovery, drug encapsulation efficiency and drug entrapment was performed using the following equations [29]:

$$\text{Nanoparticle recovery (\%)} = \frac{\text{Mass of nanoparticle recovered}}{\text{Mass of polymeric material and drug used}} \times 100$$

$$\text{Drug content (\%)} = \frac{\text{Mass of drug in nanoparticles}}{\text{Mass of nanoparticles recovered}} \times 100$$

$$\text{Drug entrapment (\%)} = \frac{\text{Mass of drug in nanoparticles}}{\text{Mass of drug used in the formulation}} \times 100$$

Preparation of Standard Solutions

A cefotaxime sodium stock solution (50 $\mu\text{g mL}^{-1}$) was freshly prepared by

dissolving the drug in 0.04 M $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ buffer solution (pH 5.5). The standard solutions were obtained by serial dilutions of the stock solution with the same buffer to give different concentrations over the range of interest ($0.2\text{--}50 \mu\text{g mL}^{-1}$). Upon preparation all solutions were covered with aluminum foil in order to protect them from light.

Preparation of Sample Solutions for Cefotaxime Sodium Quantitation in Nanoparticles

Sample solutions were prepared by dissolving 150 mg of freeze-dried cefotaxime sodium loaded nanoparticles in 0.04 M $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ buffer solution (pH 7, adjusted with glacial acetic acid) under sonication. This pH was selected in order to achieve a complete dissolution of the used polymers, since the maximum pH thresholds are 5.5 for Eudragit L100-55, 6.0 for Eudragit L100 and 7.0 for Eudragit S100 [30]. A 250 μL aliquot of the previous solution was further diluted to 25 mL with the same phosphate buffer but with a pH of 5.5 (adjusted with glacial acetic acid), which corresponds to the maximum cefotaxime sodium stability. Then, samples were subjected to LC analysis. All analyses were performed in quadruplicate.

Statistical Analysis

Analysis of variance (ANOVA) was used to validate statistically the differences among the entrapment values of cefotaxime sodium in nanoparticles. Analysis was performed using SPSS 12 (SPSS, Chicago, IL, USA).

Method Validation

The procedures and parameters adopted for the validation of the chromatographic method in this study are those described in the ICH guidelines [26, 27], which are similar to the ones established by the USP 29 [28]. The following parameters were determined: specificity,




Fig. 2. Representative chromatograms obtained following injection of **a** cefotaxime standard solution ($3.13 \mu\text{g mL}^{-1}$), **b** cefotaxime standard solution ($0.78 \mu\text{g mL}^{-1}$) spiked with Eudragit L100 nanoparticles, **c** cefotaxime standard solution ($1.56 \mu\text{g mL}^{-1}$) spiked with Eudragit L100-55 nanoparticles and **d** cefotaxime standard solution ($3.13 \mu\text{g mL}^{-1}$) spiked with Eudragit S100 nanoparticles

Table 1. Summary of standard curve results

Concentration of cefotaxime ($\mu\text{g mL}^{-1}$)	Average peak height (V)	CV (%)
0.20	538	1.48
0.39	1,102	1.91
0.78	2,102	0.50
1.56	3,868	1.35
3.13	7,995	1.08
6.25	15,937	0.91
12.50	31,841	1.02
25.00	63,947	0.49
50.00	127,973	0.61

y -Intercept = 0.63201 ± 79.86 and Slope = $2,555.92 \pm 2.04$, with confidence limits $P = 0.05$; correlation coefficient (r) = 0.99998; coefficient of determination (R^2) = 0.99997

range and linearity, precision, accuracy, DL, QL, robustness and system suitability test.

Specificity

ICH defines specificity as the ability to assess unequivocally the analyte in the presence of components that may be expected to be present, such as impurities, degradation products and matrix components. In practice, this can be performed by spiking the drug substance with appropriate levels of impurities/excipients and demonstrating that the assay results are unaffected by the presence of these potential interferences [26, 27]. In the present study, the specificity of the analytical method was determined by comparing the results from the analysis of cefotaxime standard solutions over the range of interest ($0.2\text{--}50 \mu\text{g mL}^{-1}$) and the same standards spiked with blank nanoparticles prepared with each type of Eudragit.

Linearity and Range

The linearity of an analytical method is its ability to produce test results that are directly proportional to the concentration of analyte in the sample, within a given range [27]. In the present study, linear regression was performed by plotting average peak height (y) versus the analyte concentration (x) in the concentration range of $0.2\text{--}50 \mu\text{g mL}^{-1}$.

Calibration curves were constructed at nine concentration levels using the linear-squares regression procedure. The overall experiments were repeated six times on different days. The obtained peak height values were averaged at each concentration.

Accuracy

The accuracy of an analytical method expresses the closeness of agreement between the value that is accepted either as a conventional true value (or an accepted reference value) and the achieved experimental value [27]. Accuracy is normally calculated as the percentage of recovery by the assay of known spiked amounts of analyte into the sample. In the present study, to assess the accuracy of the proposed method, recovery experiments were carried out by spiking known amounts of cefotaxime sodium to blank nanoparticles (L100, L100-55 and S100) to achieve final theoretical concentrations of cefotaxime sodium between 0.2 and $50 \mu\text{g mL}^{-1}$. Experiments were done at nine concentration levels. For each level, drug content was determined in replicates ($n = 6$).

Precision

The precision of an analytical method is the degree of agreement among individual test results when the method is applied repeatedly to multiple samplings of a homogeneous sample [27]. It is normally expressed as the coefficient of variation in percentage (CV) for a significant number of samples. Precision may be measured as repeatability, reproducibility and intermediate precision. Since reproducibility refers to the use of analytical procedure in different laboratories, for this specific case we have studied repeatability (intra-assay precision) and intermediate precision. To determine intra-assay precision six replicates of standard solutions (nine different concentrations) were analyzed by the same analyst within the same day. Intermediate precision of the assay was determined by analysis of the same standard solutions on six consecutive days by the same analyst.

Detection Limit and Quantitation Limit

The detection limit (DL) is defined as the lowest concentration of the analyte in a sample that can be detected by the method of analysis [27]. The quantitation limit (QL) is defined as the lowest concentration of the analyte in sample that can be determined with acceptable precision and accuracy under stated operational conditions for the method. In the present work, DL and QL were calculated according to the referred ICH guideline, from the slope and the standard deviation of the y -intercept of the mean of six calibration curves, as it follows:

$$DL = \frac{3.3\sigma}{S}$$

$$QL = \frac{10\sigma}{S}$$

where σ is the standard deviation of y -intercepts of regression lines and S is the slope of the calibration curves.

Robustness

The evaluation of robustness should be considered in order to ensure that the validity of the analytical procedure is maintained whenever used, even for small variations on analytical solutions [26, 27]. In this study, robustness was evaluated as the percentage of recovery by the assay when deliberate variations of pH or media composition on cefotaxime solutions were performed. This approach can predict the method applicability to pH variations/media composition during sample handling and in vitro testing.

Recovery experiments were carried out by measuring cefotaxime sodium on standard solutions ($125 \mu\text{g mL}^{-1}$) prepared at different pH values (1.0; 4.0; 4.3; 4.6; 5.0 and 7.0) and on USP 29 simulated gastric and intestinal fluids. Experiments were done in replicates ($n = 4$). Buffer solution pH 1.0 ± 0.1 consisted in 0.1 M HCl . All the other buffer solutions (pH 4.0 ± 0.1 , 4.3 ± 0.1 , 4.6 ± 0.1 , 5.0 ± 0.1 and 7.0 ± 0.1) were composed by $0.05 \text{ M NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ and the respective pH values were adjusted with glacial acetic acid. Upon preparation, the cefotaxime

sodium standard solutions were incubated at 37 °C in a dissolution tester vessel (Vankel VK 7000 dissolution tester, Vankel, Cary, NC, USA) with the paddle speed rotating at 100 rpm. At pre-established times 1 mL samples were collected and replaced by fresh medium. Aliquots were further diluted with 9 mL of 0.5 M ammonium acetate buffer solution and a mixture with pH of 5.5 was obtained. The amount of cefotaxime in the samples was immediately analyzed after collection by the proposed LC method.

Results and Discussion

Specificity

Figure 2a shows a representative chromatogram of a cefotaxime sodium standard solution ($3.13 \mu\text{g mL}^{-1}$) with a retention time of 6.3 min. Figure 2b–d show representative chromatograms obtained for cefotaxime sodium standard solutions of different concentrations (0.78; 1.56 and $3.13 \mu\text{g mL}^{-1}$) spiked with a fixed amount of blank nanoparticles ($\leftrightarrow 0.375 \text{ mg}$ of nanoparticles mL^{-1} in the final solution) prepared with each one of the three Eudragit polymers (L100, L100-55 and S100). The total running time for the samples was 10 min. No peak from possible degradation products was observed in the chromatograms, as mentioned in other studies [31], showing the purity and stability of cefotaxime sodium in the studied conditions. The absence of any peak or interference at the elution point of cefotaxime rendered the method specific.

Linearity and Range

Regression statistics are summarized in Table 1. The assay was linear with a CV of 4.1% in the response factors (peak height divided by concentration) in the tested concentration range and coefficients of correlation (r) and determination (R^2) were found to be higher than 0.9999, indicating a functional linear relationship (over 99.99%) between the

Table 2. Recovery of cefotaxime from nanoparticle formulations prepared with different Eudragit types

Theoretical cefotaxime concentration ($\mu\text{g mL}^{-1}$)	Eudragit L100 nanoparticles ^a		Eudragit L100-55 nanoparticles ^a		Eudragit S100 nanoparticles ^a	
	Recovery (%)	CV (%)	Recovery (%)	CV (%)	Recovery (%)	CV (%)
0.20	98.3	1.1	100.7	2.7	99.0	2.4
0.39	99.5	2.0	100.4	2.0	98.8	1.3
0.78	101.0	2.7	100.3	1.5	101.9	1.8
1.56	100.9	1.5	99.6	1.1	100.3	1.2
3.13	99.4	1.0	99.5	1.0	102.3	2.5
6.25	99.6	3.2	99.0	1.2	100.2	2.8
12.5	101.3	1.7	98.2	1.7	99.8	1.0
25.0	100.2	1.2	99.3	3.0	100.5	2.1
50.0	100.1	3.0	99.4	3.2	99.1	1.5
Overall mean recovery (%) and CV (%)	100.0	1.9	99.6	1.9	100.2	1.8

^a $n = 6$

Table 3. Results of precision of the chromatographic method

Theoretical cefotaxime concentration ($\mu\text{g mL}^{-1}$)	Mean experimental concentration ($\mu\text{g mL}^{-1}$)	CV (%)
Repeatability (intra-assay precision) ^a		
0.20	0.199	1.0
0.39	0.388	0.7
0.78	0.788	1.5
1.56	1.564	2.3
3.13	3.135	1.9
6.25	6.247	1.8
12.5	12.473	1.2
25.0	25.006	2.4
50.0	49.965	2.1
Intermediate precision ^a		
0.20	0.199	1.7
0.39	0.390	1.8
0.78	0.782	1.8
1.56	1.559	1.2
3.13	3.133	0.7
6.25	6.249	1.5
12.5	12.488	2.4
25.0	24.999	2.5
50.0	49.969	1.0

^a $n = 6$

concentration of cefotaxime sodium in buffer solutions and the peak height. Results demonstrate good linearity in the studied range, meeting the criteria proposed by Epshtein [32].

Accuracy

Table 2 summarizes the accuracy results, expressed as percent recovery and CV. Recovery values were within the ranges of 98.3–101.0% (CV = 1.0–3.2), 98.2–

100.7% (CV = 1.0–3.2) and 98.8–102.3% (CV = 1.0–2.8) for Eudragit L100, Eudragit L100-55 and Eudragit S100 nanoparticles, respectively. Overall mean recovery values were 100.0% ($n = 54$) for Eudragit L100 nanoparticles, 99.6% ($n = 54$) for Eudragit L100-55 nanoparticles and 100.2% ($n = 54$) for Eudragit S100 nanoparticles. Because the mean recovery results were within an acceptable $\pm 3\%$ range (1.84–1.93%), according to Segall et al. [33] the method was deemed accurate.

Table 4. Intra-assay precision of the entire analytical method for quantitation of cefotaxime from nanoparticle formulations prepared with different Eudragit types

Theoretical cefotaxime concentration ($\mu\text{g mL}^{-1}$)	Eudragit L100 nanoparticles ^a		Eudragit L100-55 nanoparticles ^a		Eudragit S100 nanoparticles ^a	
	Mean experimental concentration ($\mu\text{g mL}^{-1}$)	CV (%)	Mean experimental concentration ($\mu\text{g mL}^{-1}$)	CV (%)	Mean experimental concentration ($\mu\text{g mL}^{-1}$)	CV (%)
0.20	0.198	2.7	0.201	1.4	0.199	1.0
0.39	0.393	1.9	0.389	1.4	0.385	1.6
0.78	0.782	1.8	0.772	1.4	0.784	1.7
1.56	1.553	1.2	1.563	0.9	1.558	2.2
3.13	3.125	2.5	3.134	0.2	3.129	2.4
6.25	6.254	2.8	6.244	0.1	6.249	1.8
12.5	12.493	1.0	12.498	1.0	12.503	1.4
25.0	24.996	0.7	25.003	0.8	24.999	1.7
50.0	50.005	1.5	49.997	1.5	50.002	0.9
CV average (%)		1.8		1.0		1.6

^a $n = 6$

Table 5. Intermediate precision of the entire analytical method for quantitation of cefotaxime from nanoparticle formulations prepared with different Eudragit types

Theoretical cefotaxime concentration ($\mu\text{g mL}^{-1}$)	Eudragit L100 nanoparticles ^a		Eudragit L100-55 nanoparticles ^a		Eudragit S100 nanoparticles ^a	
	Mean experimental concentration ($\mu\text{g mL}^{-1}$)	CV (%)	Mean experimental concentration ($\mu\text{g mL}^{-1}$)	CV (%)	Mean experimental concentration ($\mu\text{g mL}^{-1}$)	CV (%)
0.20	0.198	1.6	0.201	1.1	0.193	2.4
0.39	0.389	1.6	0.392	1.7	0.391	0.5
0.78	0.788	1.0	0.782	1.8	0.786	0.8
1.56	1.568	0.2	1.554	2.4	1.563	0.7
3.13	3.119	1.6	3.128	2.5	3.129	1.0
6.25	6.244	0.1	6.234	2.6	6.239	1.6
12.5	12.399	0.6	12.293	0.5	12.463	1.7
25.0	25.018	0.9	24.899	0.8	25.099	2.2
50.0	50.030	0.8	49.975	0.7	50.045	1.6
CV average (%)		0.9		1.6		1.4

^a $n = 6$

Table 6. Results of recovery and CV for cefotaxime from standard solutions ($125 \mu\text{g mL}^{-1}$) of different pH

Time (h)	pH = 1.0 ^a		pH = 4.0 ^a		pH = 4.3 ^a		pH = 4.6 ^a		pH = 5.0 ^a		pH = 7.0 ^a	
	Mean recovery (%)	CV (%)	Mean Recovery (%)	CV (%)	Mean Recovery (%)	CV (%)	Mean Recovery (%)	CV (%)	Mean Recovery (%)	CV (%)	Mean Recovery (%)	CV (%)
0.5	97.1	1.7	100.2	0.5	100.6	0.6	101.2	1.6	99.8	0.4	99.5	0.7
1	94.5	2.4	99.6	0.7	99.6	0.7	100.5	1.5	99.4	0.5	99.0	0.8
2	86.7	1.5	99.6	1.8	99.6	0.8	99.9	1.1	98.8	1.0	99.1	1.0
4	75.0	0.6	98.3	0.9	98.3	1.4	98.4	0.9	97.8	0.5	96.8	1.2
6	61.7	2.2	96.7	1.9	96.7	1.7	97.1	0.8	96.8	0.7	97.0	0.9
8	41.6	2.1	96.3	2.2	96.3	1.5	96.8	1.1	96.4	0.6	96.9	1.3
24	–	–	95.9	2.4	95.9	2.1	95.2	2.0	95.8	0.5	96.3	1.5

^a $n = 4$

Precision

Table 3 summarizes precision of the chromatographic method. Tables 4 and 5 summarize precision of the total ana-

lytical method, both intra-day and intermediate precision, respectively. Obtained CV values varied from 0.5 to 1.9 for the chromatographic method and 1.0–1.8 for intra-assay precision and

from 0.9 to 1.6 for intermediate precision for the total analytical method, indicating that the used LC methodology showed acceptable precision, in agreement with the criteria proposed by

Shabir [34], for which the mean CV value should be lower than 2%.

Detection Limit and Quantitation Limit

For the calculation of DL and QL the calibration equations for cefotaxime sodium were generated by using the mean values of the six independent calibration curves. The obtained DL and QL values were 0.045 and 0.135 $\mu\text{g mL}^{-1}$, respectively (i.e., the method is sensitive enough to detect 0.045 $\mu\text{g mL}^{-1}$ and quantitate 0.135 $\mu\text{g mL}^{-1}$ of cefotaxime sodium in the studied conditions).

Robustness

Tables 6 and 7 summarize the robustness results, expressed as percent recovery and CV. As expected, for cefotaxime solutions prepared either at pH 1.0 or on USP 29 simulated gastric fluid, low recovery values ($\approx 40\%$) were obtained at the end of 8 h of incubation. Fabre et al. [35] also reported a marked decrease of the cefotaxime concentration at pH 1.6 with a 40% recovery after 8 h, due to the hydrolysis of the drug. Moreover, high CV values were observed, revealing a low degree of reproducibility of the results obtained in referred conditions.

For standard solutions prepared either at pH 4; 4.3; 4.6; 5 and 7, during 24 h of incubation, or on simulated intestinal fluid (during 8 h), high recovery and low CV values were obtained. Cefotaxime sodium standard solutions in the pH range 4–7 showed recovery values between 95.2 and 96.3% (CV = 0.5–2.4%) at the end of 24 h.

On simulated intestinal medium at the end of 8 h, 90% of recovery (CV = 2.0%) were obtained. These results indicate that, for the pH range 4–7, the analytical procedure is robust with respect to sample pH. This pH range comprises the pH values at which cefotaxime is exposed during the production of nanoparticles and release studies in USP 29 simulated intestinal fluid (pH 6.8 ± 0.1). Therefore, the analytical procedure allows its use for cefotaxime sodium quantitation either in

Table 7. Results of recovery and CV for cefotaxime from standard solutions ($125 \mu\text{g mL}^{-1}$) prepared in USP 29 simulated gastric and intestinal fluids

Time (h)	Simulated gastric fluid ^a		Simulated intestinal fluid ^a	
	Mean recovery (%)	CV (%)	Mean recovery (%)	CV (%)
0.5	96.13	1.0	100.13	0.9
1	93.25	1.1	99.43	1.2
2	85.83	1.4	98.58	1.6
4	70.55	2.2	94.75	1.4
6	55.53	2.4	91.43	2.1
8	36.73	3.2	90.00	2.0

^a $n = 4$

Table 8. Results of the system suitability test

Parameter	Cefotaxime sodium ^a			
	Minimum	Maximum	CV (%)	Status
Retention time (min)	6.309	6.399	0.55	Passed
Peak height (V)	137645	142199	1.25	Passed

^a $n = 4$

nanoparticle dispersions or in the release studies from the nanoparticulate systems. Interestingly, cefotaxime recovery in simulated intestinal medium (90.0%) was lower than that observed for the pH 7 solution (96.3%). This loss of drug may be attributed to cefotaxime metabolism by pancreatin present in simulated intestinal fluid, as previously described for vancomycin by Claudius and Neau [36].

The system suitability test was also carried out to evaluate the reproducibility of the system for the analysis to be performed, using six replicate injections of a cefotaxime sodium standard solution ($50 \mu\text{g mL}^{-1}$) prepared in a 0.04 M $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ buffer solution (pH 5.5). The results given in Table 8 show that the evaluated parameters are within the suitable range, as proposed by Dal-mora et al. [37].

Application of the LC Method for the Quantitation of Cefotaxime Sodium in Nanoparticles

The analytical method was shown to be effective, fast and meeting all criteria for method validation and was applied to the quantitation of cefotaxime sodium which was incorporated for the first time in Eudragit pH-sensitive nanoparticles.

Figure 3a–c show representative chromatograms of nanoparticles containing cefotaxime sodium prepared with different types of Eudragit (L100, L100-50 and S100). None of the chromatograms showed any interfering peaks.

Table 9 shows the physicochemical characterization parameters of nanoparticles, such as the mean particle size, polydispersity index, zeta potential and drug entrapment. Nanoparticles presented a mean size of approximately 100 nm with a narrow size distribution and negative zeta potential. However, their negativity varied with the Eudragit type used, being more marked for S100 nanoparticles (-26.9 ± 1.7 mV) and less marked for L100 nanoparticles (-12.3 ± 0.5 mV). Drug entrapment values were low in all cases, ranging between 4.3 and 5.0%, and their differences were not statistically significant ($P > 0.05$). Low entrapment efficiencies of cefotaxime sodium in Eudragit nanoparticles prepared by the current method are due to the high water solubility of the drug which migrates towards the external aqueous phase during the nanoparticle formation. This phenomenon is even more pronounced due to the small size of the nanoparticles and hence their large surface area, as they undergo drug loss into the aqueous phase during formation. A similar explanation was




Fig. 3. Representative chromatograms of **a** cefotaxime loaded Eudragit L100 nanoparticles ($4.47 \mu\text{g mL}^{-1}$), **b** cefotaxime loaded Eudragit L100-55 nanoparticles ($4.32 \mu\text{g mL}^{-1}$) and **c** cefotaxime loaded Eudragit S100 nanoparticles ($4.03 \mu\text{g mL}^{-1}$)

Table 9. Physicochemical parameters of cefotaxime-loaded pH-sensitive nanoparticles

Physicochemical parameters	Eudragit L100 nanoparticles ^a	Eudragit L100-55 nanoparticles ^a	Eudragit S100 nanoparticles ^a
Mean size (nm)	99.8 ± 3.1	99.5 ± 2.2	94.4 ± 4.0
PDI ^b	0.177 ± 0.005	0.099 ± 0.005	0.226 ± 0.019
Zeta potential (mV)	-12.3 ± 0.5	-22.8 ± 3.2	-26.9 ± 1.7
Drug entrapment (%)	4.3 ± 0.3	4.8 ± 0.1	5.0 ± 0.3

^a Values express the mean results \pm SD values of four different batches ($n = 4$)

^b Varies from 0.0 corresponding to a perfect homogeneous dispersion to 1.0 corresponding to a complete heterogeneous dispersion

proposed by Govender et al. [29] for the incorporation of a water soluble drug (procaine hydrochloride) in nanoparticles.

Conclusions

A simple isocratic reverse-phase LC method was validated for the determination of cefotaxime sodium in different Eudragit type nanoparticles, which was entrapped for the first time in these nanocarriers. The proposed method is simple, sensitive, reproducible and requires a small sample volume. Obtained results showed that it is specific, linear, accurate and precise within the established range, according to ICH guidelines and USP 29.

Validated method was successfully applied to the quantitation of cefotaxime sodium content in nanoparticle formulations, affording an important tool for the quality control of finished products. Eudragit based nanosystems are under optimization in order to improve drug entrapment and oral bioavailability studies are currently being undertaken in rats.

References

- Sharma P, Chawla HP, Panchagnula R (2002) *J Pharm Biomed Anal* 27:39–50. doi:10.1016/S0731-7085(01)00506-4
- Allemann E, Leroux J, Gurny R (1998) *Adv Drug Del Rev* 34:171–189. doi:10.1016/S0169-409X(98)00039-8
- Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T (2000) *Eur J Pharm Biopharm* 50:147–160. doi:10.1016/S0939-6411(00)00084-9
- Klipstein FA, Engert RF, Sherman WT (1983) *Infect Immun* 39:1000–1003. <http://iai.asm.org/cgi/content/abstract/39/2/1000>
- Morishita I, Morishita M, Takayama K, Machida Y, Nagai T (1993) *Int J Pharm* 91:29–37. doi:10.1016/0378-5173(93)90418-F
- De Jaeghere F, Allemann E, Kubel F, Galli B, Cozens R, Doelker E, Gurny R (2000) *J Control Release* 68:291–298. doi:10.1016/S0168-3659(00)00272-8
- Dai J, Nagai T, Wang X, Zhang T, Meng M, Zhang Q (2004) *Int J Pharm* 280:229–240. doi:10.1016/j.ijpharm.2004.05.006
- Mangenheim B, Benita S (1991) *STP Pharma Sci* 1:221–241
- Kreuter J, Munz K (1989) *Int J Pharm* 55:39–45. doi:10.1016/0378-5173(89)90274-3
- McClellan S, Prosser E, Meehan E, O'Malley D, Clarke N, Ramtoola Z,

- Brayden D (1998) *Eur J Pharm Sci* 6:153–163. doi:10.1016/S0928-0987(97)10007-0
11. Pereira RE, Julianto TB, Yuen KH, Majeed ABA (2008) *EPharmaNexus* 01:34–43
 12. Teixeira M, Afonso CM, Pinto MM, Barbosa CM (2003) *J Chromatogr Sci* 41:371–376. <http://www.j-chrom-sci.com/abstracts/2003/August/371-barbosa.html>
 13. Teixeira M, Afonso CM, Pinto MM, Barbosa CM (2008) *J Chromatogr Sci* 46:472–478. <http://www.j-chrom-sci.com/abstracts/2008/July/472-teixeira.html>
 14. Bergan T, Solberg R (1981) *Chemotherapy* 27:155–165. doi:10.1159/000237972
 15. Lecaillon JB, Rouan MC, Soupert C, Fevre N, Judge F (1982) *J Chromatogr Biomed Appl* 228:257–267. doi:10.1016/S0378-4347(00)80438-7
 16. Signs SA, File TM, Tan JS (1984) *Antimicrob Agents Chemother* 26:652–655. doi:10.1128/AAC
 17. Scanes T, Hundt AF, Swart KJ, Hundt HK (2001) *J Chromatogr B Biomed Sci Appl* 750:171–176. doi:10.1016/S0378-4347(00)00417-5
 18. Dell D, Chamberlain J, Coppin F (1981) *J Chromatogr* 226:431–440. doi:10.1016/S0378-4347(00)86077-6
 19. Jehl F, Birckel P, Monteil H (1987) *J Chromatogr* 413:109–119. doi:10.1016/0378-4347(87)80218-9
 20. Yost RL, Derendorf H (1985) *J Chromatogr* 341:131–138. doi:10.1016/S0378-4347(00)84017-7
 21. Patel KB, Nicolau DP, Nightingale CH, Quintiliani R (1996) *Antimicrob Agents Chemother* 40:2805–2808. <http://aac.asm.org/cgi/content/abstract/40/12/2805>
 22. Brisson AM, Fourtillan JB (1981) *J Chromatogr* 223:393–399. doi:10.1016/S0378-4347(00)80112-7
 23. Bertels RA, Semmekrot BA, Gerrits GP, Mouton JW (2008) *Infection* 36:415–420. doi:10.1007/s15010-008-7274-1
 24. Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA (2009) *Antimicrob Agents Chemother* 53:75–80. doi:10.1128/AAC.00636-08
 25. Seguin P, Verdier MC, Chanavaz C, Enggrand C, Laviolle B, Donnio PY, Mallédant Y (2009) *J Antimicrob Chemother* 63:564–567. doi:10.1093/jac/dkn522
 26. European Commission, Directorate General III-Industry Pharmaceuticals and Cosmetics (1998) Validation of analytical procedures: methodology. The rules governing medicinal products in European Union, 3A:107–117
 27. European Commission, Directorate General III-Industry Pharmaceuticals and Cosmetics (1998) Validation of analytical procedures: definition and terminology. The rules governing medicinal products in European Union, 3A:119–125
 28. United States Pharmacopeia 29/NF 24 (2005) Validation of compendial methods and test solutions. US Pharmacopeial Convention, Rockville, Maryland, USA, pp 3050–3052
 29. Govender T, Riley T, Ehtezazi T, Garnett MC, Stolnik S, Illum L, Davis SS (2000) *Int J Pharm* 199:95–110. doi:10.1016/S0378-5173(00)00375-6
 30. Ceballos A, Cirri M, Maestrelli F, Corti G, Mura P (2005) *Il Farmaco* 60:913–918. doi:10.1016/j.farmac.2005.07.002
 31. Zendelovska D, Stafilov T, Milosevski P (2003) *Bull Chem Technol Macedonia* 22:39–45
 32. Epshtein N (2004) *Pharm Chem J* 38:212–228. doi:10.1023/B:PHAC.0000038422.27193.6c
 33. Segall A, Hormaechea F, Vitale M, Perez V, Pizzorno MT (1999) *J Pharm Biomed Anal* 19:803–808. doi:10.1016/S0731-7085(98)00120-4
 34. Shabir GA (2004) *Pharm Technol Eur* 37–49. <http://pharmtech.findpharma.com/pharmtech/Analytical/HPLC-Method-Development-and-Validation-for-Pharmac/ArticleLong/Article/detail/89002>
 35. Fabre H, Eddine NH, Berge G (1984) *J Pharm Sci* 73:188–611. doi:10.1002/jps.2600730508
 36. Claudius JS, Neau SH, Kenny MT, Dulworth JK (1999) *J Pharm Pharmacol* 51:1333–1337. <http://www.ingentaconnect.com/content/rpsgb/jpp/1999/00000051/00000011/art00017>
 37. Dalmora SL, Sangoi Mda S, da Silva LM, Macedo RO, Barth T (2008) *J Sep Sci* 31:169–176. doi:10.1002/jssc.200700272